Novel Heart Failure Drug From Novartis Gains 'Breakthrough Therapy ... Forbes Serelaxin, the novel therapy under development for the treatment of acute heart failure, has received a “breakthrough therapy” designation from the FDA, according to Novartis, the company developing the drug. The designation, the FDA explains, “is ... |
